Peer-reviewed veterinary case report
Eye drops with omidenepag lower eye pressure in normal and glaucoma
By Oikawa, Kazuya et al.Ā·Published in Veterinary ophthalmologyĀ·2026Ā·University of Wisconsin-Madison, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Topical Omidenepag Isopropyl Lowers Intraocular Pressure in Normal and Glaucomatous Cats: A Pilot Study.
- Species:
- cat
Plain-English summary
A group of cats with congenital glaucoma and some normal cats were given a single drop of a new eye drop medication called omidenepag isopropyl to see if it could lower their eye pressure. The results showed that this treatment significantly reduced eye pressure in both groups, with the greatest decrease seen in the cats with glaucoma. The normal cats had a reduction of about 7.3 mmHg, while the glaucoma cats had a reduction of about 16.7 mmHg. Importantly, there were no side effects like pupil constriction or irritation noted. This suggests that omidenepag isopropyl could be a good option for treating glaucoma in cats.
People also search for: cat glaucoma treatment Ā· eye drops for cat eye pressure Ā· omidenepag isopropyl for cats
Abstract
PURPOSE: To evaluate the effects of topical prostaglandin E2 receptor 2 (EP2) agonist, omidenepag isopropyl (OMDI), on intraocular pressure (IOP) and pupil diameter (PD) in normal cats and cats with feline congenital glaucoma (FCG). ANIMALS STUDIED: Ten FCG cats and 8 normal cats. METHODS: In this prospective, randomized, placebo-controlled, masked pilot study, normal and FCG cats received one drop of 0.002% OMDI ophthalmic solution in one eye and artificial tears in the contralateral eye. IOP and PD were measured by a masked observer at baseline and at multiple time points up to 32-36 h post-administration. RESULTS: Topical 0.002% OMDI significantly lowered IOP compared to controls in both normal and FCG cats. In normal cats, the effect was significant up to 12 h after instillation, with a maximal reduction from baseline of 7.3 mmHg (43.5%). In FCG cats, the effect was significant from 2 to 8 h after instillation, with a maximal reduction from baseline of 16.7 mmHg (60.2%). No significant effect on pupil diameter or signs of ocular irritation was observed in either group. CONCLUSIONS: A single topical drop of 0.002% OMDI significantly lowers IOP in normal and FCG cats without inducing miosis. Our findings support that topical selective EP2 agonists may be a promising therapeutic option for feline glaucoma and provide information relevant to dosing intervals for future studies.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41332294/